IPCALAB2021-04-012021-06-30in-bse-fin:OneOperatingExpenses01Member IPCALAB2021-04-012021-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member IPCALAB2021-04-012021-06-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member IPCALAB2021-04-012021-06-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss02Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares IPCALAB 2021-04-01 2022-03-31 2021-07-22 INR Crores First quarter Single segment Pharmaceuticals 2021-04-01 2021-06-30 Unaudited Standalone 14786000000.00 136100000.00 14922100000.00 4040800000.00 521400000.00 419700000.00 2806400000.00 12600000.00 499600000.00 3057900000.00 11358400000.00 3563700000.00 0.00 3563700000.00 625000000.00 91500000.00 716500000.00 0.00 2847200000.00 0.00 0.00 0.00 0.00 2847200000.00 -2300000.00 2844900000.00 0.00 0.00 253700000.00 2 22.45 22.45 0.00 0.00 22.45 22.45 1.The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on August 5, 2021 .The Statutory Auditors have carried out the limited review of the results. 2 *The figures for the quarter ended March 31,2021 are the balancing figures between audited figures in respect of the full financial year 2020-21 and the published year to date unaudited figures upto December 31,2020. 3 The Company has only one operating segment viz. 'Pharmaceuticals'. 4 Figures for the previous periods have been regrouped / re-classified to conform to the figures of the current period. Other Expenes 3057900000.00